uniQure (QURE) Projected to Post Earnings on Tuesday

Key Points

• uniQure will report Q1 2026 results before the market opens on May 5, 2026, with analysts forecasting EPS of ($0.7527) and revenue of $4.493 million.
• The company said it had a successful UK MHRA pre‑submission meeting for AMT‑130 and expects to file a UK Marketing Authorization Application in Q3 2026, a catalyst that has prompted analyst upgrades and a recent ~19% stock surge.
• uniQure beat the prior quarter's estimates (EPS -$0.56 vs. -$0.93; revenue $5.57M) but remains unprofitable with large negative margins and recent insider selling; the Street consensus is a "Moderate Buy" with a $43.33 average target price.

uniQure (NASDAQ:QURE - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.7527) per share and revenue of $4.4930 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.93) by $0.37. The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, analysts expect uniQure to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

uniQure Stock Up 19.2%

Shares of NASDAQ:QURE opened at $19.95 on Friday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The firm has a 50 day simple moving average of $16.75 and a 200-day simple moving average of $26.01. The company has a market capitalization of $1.26 billion, a PE ratio of -5.78 and a beta of 0.75. uniQure has a twelve month low of $8.73 and a twelve month high of $71.50.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure announced a successful UK MHRA pre‑submission meeting and said it expects to file a UK Marketing Authorization Application for AMT‑130 in Q3 2026 — a clear near‑term regulatory pathway that supports upside if the MHRA review proceeds smoothly. uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
• Positive Sentiment: Market outlets and company filings reiterate the pre‑submission success and advancement toward UK marketing approval — this reduces short‑term regulatory uncertainty for AMT‑130 and is being treated as a validating event by investors. uniQure advances AMT-130 toward UK marketing approval
• Positive Sentiment: Major outlets frame the MHRA outcome as a “symbolic” regulatory win and catalog the company’s intent to pursue UK approval — positive press flow is amplifying investor interest. UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
• Positive Sentiment: Analyst momentum: Chardan Capital raised its price target from $31 to $37 and moved to a Buy rating, providing an upgraded sell‑side thesis and signaling perceived upside vs. the prior level. Benzinga
• Neutral Sentiment: News coverage notes the stock’s intraday bounce and coverage of the MHRA meeting; these pieces summarize developments rather than add new data, but they help liquidity and visibility. UniQure rises after regulatory updates on gene therapy
• Neutral Sentiment: Additional summaries and analyst writeups reiterate the timing and next steps for the UK filing — useful for tracking but not new catalytic data. QURE stock just shot up 8% - uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost
• Negative Sentiment: Some reporting frames the UK move as a response to past FDA friction — the program remains “embattled” after disagreements with the FDA, highlighting ongoing regulatory risk in other jurisdictions (notably the U.S.). That unresolved FDA situation is a material downside risk. UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on QURE. Wells Fargo & Company upgraded uniQure from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $15.00 to $60.00 in a research report on Monday, March 9th. TD Cowen reiterated a "buy" rating on shares of uniQure in a research note on Tuesday, March 3rd. Wolfe Research initiated coverage on shares of uniQure in a research report on Monday, February 23rd. They set a "peer perform" rating on the stock. Royal Bank Of Canada raised shares of uniQure from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $11.00 to $35.00 in a report on Monday, March 9th. Finally, The Goldman Sachs Group boosted their target price on uniQure from $9.00 to $10.00 and gave the company a "neutral" rating in a report on Monday, April 20th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $43.33.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 14,581 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the completion of the sale, the chief executive officer owned 660,658 shares of the company's stock, valued at approximately $5,985,561.48. This trade represents a 2.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeannette Potts sold 3,412 shares of the company's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the transaction, the insider directly owned 138,483 shares in the company, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 49,396 shares of company stock valued at $722,734. Corporate insiders own 4.79% of the company's stock.

Institutional Trading of uniQure

A number of institutional investors have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC acquired a new position in uniQure during the third quarter worth about $50,000. Smartleaf Asset Management LLC purchased a new stake in shares of uniQure during the 4th quarter worth approximately $48,000. Ensign Peak Advisors Inc boosted its stake in shares of uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company's stock worth $87,000 after acquiring an additional 650 shares in the last quarter. Knott David M Jr grew its holdings in shares of uniQure by 100.0% in the 4th quarter. Knott David M Jr now owns 4,000 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 2,000 shares during the period. Finally, Deutsche Bank AG increased its stake in uniQure by 98.3% in the 4th quarter. Deutsche Bank AG now owns 4,621 shares of the biotechnology company's stock valued at $111,000 after purchasing an additional 2,291 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.